Skip to main content
PMC home page
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2019 Jul 1.
Published in final edited form as: Clin Gastroenterol Hepatol. 2018 Mar 15;16(7):1174. doi: 10.1016/j.cgh.2018.03.011

Predictors of Response to Terlipressin in Hepatorenal Syndrome

Ayse L Mindikoglu 1,2, Stephen C Pappas 2
PMCID: PMC6008198  NIHMSID: NIHMS951724  PMID: 29551736

Dear Editor

We would like to thank Dr. Satsangi for his appreciation and valuable comments in his Letter to the Editor regarding our recent review article on “New Developments in Hepatorenal Syndrome”.1 Previous studies have shown that baseline serum creatinine and total bilirubin levels, grade of acute-on-chronic liver failure, and mean arterial pressure were independent predictors of response to terlipressin in hepatorenal syndrome.2–5 In addition to these conventional predictors, a new metabolomic signature associated with hepatorenal dysfunction and mortality in cirrhosis appears promising, and should be evaluated in predicting response to terlipressin in hepatorenal syndrome.6

Acknowledgments

Funding

This project was supported in part by NIH Public Health Service grant P30DK056338, which funds the Texas Medical Center Digestive Diseases Center and its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Institute of Diabetes and Digestive and Kidney Diseases or the NIH.

Footnotes

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Disclosures:

Ayse L. Mindikoglu, M.D., M.P.H. A provisional patent application (serial no. 62/586,966) is filed with the U.S. Patent and Trademark Office on November 16, 2017, entitled “Metabolomic Biomarkers of Hepatorenal Dysfunction and Mortality in Patients with Cirrhosis”.

Stephen C. Pappas, M.D. J.D., FCLM, FAASLD is a consultant for Orphan Therapeutics LLC and Ikaria Inc., a Mallinckrodt Company.

References

  • 1.Mindikoglu AL, Pappas SC. New Developments in Hepatorenal Syndrome. Clin Gastroenterol Hepatol. 2018;16:162–177. e1. doi: 10.1016/j.cgh.2017.05.041. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Boyer TD, Sanyal AJ, Garcia-Tsao G, et al. Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics. J Hepatol. 2011;55:315–21. doi: 10.1016/j.jhep.2010.11.020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Nazar A, Pereira GH, Guevara M, et al. Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology. 2010;51:219–26. doi: 10.1002/hep.23283. [DOI] [PubMed] [Google Scholar]
  • 4.Piano S, Schmidt HH, Ariza X, et al. Association Between Grade of Acute on Chronic Liver Failure and Response to Terlipressin and Albumin in Patients With Hepatorenal Syndrome. Clin Gastroenterol Hepatol. 2018 doi: 10.1016/j.cgh.2018.01.035. [DOI] [PubMed] [Google Scholar]
  • 5.Sanyal AJ, Boyer TD, Frederick RT, et al. Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies. Aliment Pharmacol Ther. 2017;45:1390–1402. doi: 10.1111/apt.14052. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Mindikoglu AL, Opekun AR, Putluri N, et al. Unique metabolomic signature associated with hepatorenal dysfunction and mortality in cirrhosis. Transl Res. 2018;195:25–47. doi: 10.1016/j.trsl.2017.12.002. [DOI] [PMC free article] [PubMed] [Google Scholar]

RESOURCES